Surface Engineering of Placenta-Derived Mesenchymal Stem Cells with ASGPR Ligands for Alleviating Liver Damage
발표자
()
초록
내용
The clinical efficacy of mesenchymal stem cells (MSCs) is often limited by poor migration and engraftment in damaged tissues. Here, we developed lipid-conjugated lactobionic acid (LA-Lipid) biomaterials to engineer the surface of placenta-derived MSCs (PDMSCs), and designed for (1) lipid-mediated anchoring onto the PDMSC membrane and (2) presentation of LA. Hepatocyte damage induces ASGPR expression, facilitating interaction between LA engineered PDMSCs (LA-PDMSCs) and ASGPR on hepatocytes, thereby activating PDMSCs to secrete therapeutic growth factors. This promotes hepatocyte regeneration and provides anti-inflammatory effects, essential for liver disease treatment. Notably, LA-PDMSCs demonstrated substantial engraftment rate, enhanced liver recovery, and anti-fibrotic effect in the liver of the BDL rat model. Overall, this method addresses technical and clinical challenges in adoptive stem cell therapy, offering an efficient approach to enhance liver recovery.